Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBITDA (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBITDA data on record, last reported at -$58.7 million in Q4 2025.

  • For Q4 2025, EBITDA fell 60.6% year-over-year to -$58.7 million; the TTM value through Dec 2025 reached $23.6 million, up 111.94%, while the annual FY2025 figure was $23.6 million, 111.94% up from the prior year.
  • EBITDA reached -$58.7 million in Q4 2025 per APLS's latest filing, down from $215.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $215.9 million in Q3 2025 and bottomed at -$219.4 million in Q2 2021.
  • Average EBITDA over 5 years is -$105.2 million, with a median of -$130.5 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 285.23% in 2021, then surged 477.27% in 2025.
  • A 5-year view of EBITDA shows it stood at -$148.0 million in 2021, then decreased by 10.69% to -$163.8 million in 2022, then surged by 44.43% to -$91.1 million in 2023, then surged by 59.89% to -$36.5 million in 2024, then crashed by 60.6% to -$58.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$58.7 million in Q4 2025, $215.9 million in Q3 2025, and -$41.7 million in Q2 2025.